AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

How to Use a Buy-Write Options Strategy With Out-Of-Favor ETFs

Financials and energy ETFs aren't faring well in the current environment, but there still is a way to make money on them.

Caution Is the Watchword of the Day in Investing

It's hard to put much stock in achieving real progress on trade talks with China, and with the yield curve inverting and global economies sagging it's time to be on guard in the markets.

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

Investing in Small Biotechs? Check Out the CFO First

They're the most important executive at most small developmental or early commercialization concerns.

3 Tariff Questions That Must Wait for Answers

It will take time to determine the impact of new tariffs on consumer prices, business bottom lines and the achievement of a trade deal with China.

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.

3 Watch Items for the Market That Don't Involve the Fed or Brexit

The trio to keep an eye on are U.S.-China trade talks, business investment and political rhetoric.

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight